Abstract 218P
Background
Adjuvant chemotherapy improved disease-free survival (DFS) among MIUC patients (pts). CheckMate 274 study demonstrated adjuvant immunotherapy improved DFS in MIUC pts. However, few studies explored the efficacy of adjuvant chemotherapy plus immunotherapy in MIUC pts. Our real-world study aimed to evaluate the effectiveness of adjuvant chemoimmunotherapy versus chemotherapy in high-risk MIUC pts.
Methods
Clinical data of high-risk MIUC pts between October 2016 and March 2023 were retrospectively collected from Sun Yat-sen University Cancer Center. After radical surgery, pT3/4 and pN+ MIUC pts without prior neoadjuvant therapy received adjuvant tislelizumab combined with GC (T+GC) or GC. In T+GC group, pts firstly received cisplatin 70 mg/m2 D2, and gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks for 2-6 cycles, then received tislelizumab 200 mg every 3 weeks for 2-17 cycles. In GC group, pts received cisplatin 70 mg/m2 D2, and gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks for 2-6 cycles. The primary outcome was DFS, and secondary outcomes were OS and safety.
Results
The median follow-up was 17.7(2.1-38.3) months, totally 117 MIUC pts were analyzed, with a median age of 64 (34-85) years. 75.2% were male, 46.2% were UTUC, 20.5% were variant histology; pT3=58.9%, pT4=17.1%; pN+=52.1%. In T+GC group (n=68), the mean number of tislelizumab cycles was 4 and GC cycles was 2.7. In GC group (n=49), the mean number of GC cycles was 2.9. The T+GC group (n=68) had a significantly longer DFS compared with the GC group (n=49) (median DFS (95% CI): 19.1 (6.0-32.5) vs 8.4 (1.0-39.4) months, HR=0.172, P<0.001). While lymphovascular invasion pts had a lower probability of DFS (HR=22.1 (2.8-173.5), P=0.003). The OS was longer in the T+GC group (n=68) (median OS (95% CI): 20.1(6.0-32.5) vs 12.2(1.5-39.4) months, P=0.186). Longer follow-up was required to determine the OS benefits in T+GC group. Grade 1-2 immune related adverse events including pruritus (n=10), ALT/AST increased (n=8), hyperthyroidism (n=5) and hyperglycaemia (n=3).
Conclusions
Our data demonstrated effectiveness of tislelizumab combined with GC as adjuvant therapy for pT3/4 and pN+ MIUC pts in real world.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract